硼替佐米在恶性血液病治疗中的应用进展  

Application of Bortezomib in the Treatment of Malignant Hematonosis

作　　者：高力[1] 张曦[1] 

机构地区：[1]第三军医大学新桥医院血液科,重庆400037

出　　处：《中国药房》2013年第38期3555-3558,共4页China Pharmacy

基　　金：国家自然科学基金资助项目(No.81070388);国家重点基础研究发展计划(973计划)资助课题子课题(No.2012CB518103)

摘　　要：目的:归纳硼替佐米在恶性血液病治疗中的应用进展。方法:对硼替佐米的结构性质、作用机制与其在恶性浆细胞病、非霍奇金淋巴瘤和白血病中的应用以及不良反应进行述评。结果与结论:蛋白酶体成为恶性血液病治疗中的重要靶点。硼替佐米在骨髓瘤的治疗中显示出独特优势,在白血病、恶性淋巴瘤等治疗中也取得了进展。以硼替佐米为核心的方案在治疗恶性血液病方面的疗效值得期待。OBJECTIVE： To summarize the application and development of bortezomib in the treatment of malignant hematono- sis. METHODS： The structure, property and mechanism of bortezomib, application of it in malignant plasma cell dyscrasias, non-Hodgkin lymphoma and leukocythemia as well as ADR were all reviewed. RESULTS＆CONCLUSIONS： Proteasomes is consid- ered as a target in malignant hematonosis therapy. Bortezomib shows unique advantage in myeloma therapy and completes some achievements in leukocythemia and lymphoma therapy, etc. Therapeutic efficacy of bortezomib-based malignant hematonosis thera- py plan will have been worth the waiting.

关 键 词：硼替佐米 恶性血液病 进展 

分 类 号：R973[医药卫生—药品] R969.3[医药卫生—药学]